CA3063625A1 - A pharmaceutical combination for the treatment of a cancer - Google Patents

A pharmaceutical combination for the treatment of a cancer Download PDF

Info

Publication number
CA3063625A1
CA3063625A1 CA3063625A CA3063625A CA3063625A1 CA 3063625 A1 CA3063625 A1 CA 3063625A1 CA 3063625 A CA3063625 A CA 3063625A CA 3063625 A CA3063625 A CA 3063625A CA 3063625 A1 CA3063625 A1 CA 3063625A1
Authority
CA
Canada
Prior art keywords
cancer
compound
abtl0812
paclitaxel
gemcitabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3063625A
Other languages
English (en)
French (fr)
Inventor
Carles Domenech Garcia
Jose Alberto Alfon Coriat
Hector Perez Montoyo
Miguel FRANCISCO SEGURA GINARD
Jose MIGUEL LIZCANO DE VEGA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ability Pharmaceuticals SA
Original Assignee
Ability Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ability Pharmaceuticals SA filed Critical Ability Pharmaceuticals SA
Publication of CA3063625A1 publication Critical patent/CA3063625A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3063625A 2017-05-16 2018-05-15 A pharmaceutical combination for the treatment of a cancer Pending CA3063625A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382282.6 2017-05-16
EP17382282 2017-05-16
PCT/EP2018/062554 WO2018210830A1 (en) 2017-05-16 2018-05-15 A pharmaceutical combination for the treatment of a cancer

Publications (1)

Publication Number Publication Date
CA3063625A1 true CA3063625A1 (en) 2018-11-22

Family

ID=58765794

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3063625A Pending CA3063625A1 (en) 2017-05-16 2018-05-15 A pharmaceutical combination for the treatment of a cancer

Country Status (16)

Country Link
US (3) US11260042B2 (https=)
EP (2) EP4234035A3 (https=)
JP (1) JP7208650B2 (https=)
KR (1) KR102569052B1 (https=)
CN (2) CN110636842A (https=)
AU (1) AU2018269462B2 (https=)
BR (1) BR112019023944A2 (https=)
CA (1) CA3063625A1 (https=)
CL (1) CL2019003288A1 (https=)
ES (1) ES2955524T3 (https=)
HU (1) HUE063275T2 (https=)
IL (1) IL270676B2 (https=)
MX (1) MX2019013683A (https=)
PL (1) PL3624786T3 (https=)
WO (1) WO2018210830A1 (https=)
ZA (1) ZA201907286B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102569052B1 (ko) * 2017-05-16 2023-08-22 어빌리티 파마슈티컬스 에스.엘. 암의 치료를 위한 약제학적 조합물
WO2021160650A1 (en) * 2020-02-10 2021-08-19 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer
CN120733048A (zh) * 2025-08-29 2025-10-03 天津医科大学总医院 一种用于治疗肺鳞癌的药物组合物及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258816A (ja) * 1987-04-16 1988-10-26 Nippon Oil & Fats Co Ltd 抗癌剤組成物
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
AU5928599A (en) * 1999-09-09 2001-04-10 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
GB0011903D0 (en) 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
RU2284818C2 (ru) 2001-05-10 2006-10-10 Анормед, Инк. Комбинированная химиотерапия
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
SG175401A1 (en) 2009-05-08 2011-12-29 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
ES2601891T3 (es) 2011-10-18 2017-02-16 Nestec S.A. Composición para su uso en crecimiento cerebral y/o desarrollo cognitivo y/o psicomotor
UA114615C2 (uk) 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
KR102569052B1 (ko) * 2017-05-16 2023-08-22 어빌리티 파마슈티컬스 에스.엘. 암의 치료를 위한 약제학적 조합물

Also Published As

Publication number Publication date
EP4234035A3 (en) 2023-11-15
HUE063275T2 (hu) 2024-01-28
US11260042B2 (en) 2022-03-01
RU2019135507A3 (https=) 2021-09-03
EP3624786C0 (en) 2023-07-05
KR102569052B1 (ko) 2023-08-22
KR20200005573A (ko) 2020-01-15
US12280033B2 (en) 2025-04-22
CN119950727A (zh) 2025-05-09
RU2019135507A (ru) 2021-06-16
PL3624786T3 (pl) 2023-10-30
EP3624786A1 (en) 2020-03-25
ES2955524T3 (es) 2023-12-04
US20210154166A1 (en) 2021-05-27
JP7208650B2 (ja) 2023-01-19
BR112019023944A2 (pt) 2020-06-09
US12053449B2 (en) 2024-08-06
WO2018210830A1 (en) 2018-11-22
EP3624786B1 (en) 2023-07-05
IL270676B2 (en) 2024-11-01
US20220257554A1 (en) 2022-08-18
CL2019003288A1 (es) 2020-05-08
AU2018269462B2 (en) 2024-04-18
EP4234035A2 (en) 2023-08-30
AU2018269462A1 (en) 2019-11-28
ZA201907286B (en) 2021-01-27
CN110636842A (zh) 2019-12-31
IL270676B1 (en) 2024-07-01
US20240350449A1 (en) 2024-10-24
IL270676A (https=) 2020-01-30
JP2020520385A (ja) 2020-07-09
MX2019013683A (es) 2020-01-15

Similar Documents

Publication Publication Date Title
US12280033B2 (en) Pharmaceutical combination for the treatment of a cancer
Marijon et al. Co-targeting poly (ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells
Johnston et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
TWI329025B (en) Compositions for delivery of drug combinations
US20240342199A1 (en) Combination therapies targeting mitochondria for cancer therapy
JP6759402B2 (ja) Ｆｌｔ３変異を有する急性骨髄性白血病の治療用の医薬組成物
JP2020105213A (ja) 病変した組織から老化細胞を除去することにより眼の疾患、肺の疾患またはアテローム性動脈硬化を処置するための医薬
WO2019126739A1 (en) Pyrvinium pamoate anti-cancer therapies
EP2832358A1 (en) Pharmaceutical kit for use in the treatment of colon and colorectal cancer
JP2014522844A (ja) 白血病を治療するための組成物、方法及びキット
JP2013512234A (ja) 小型ピリミジン誘導体およびその使用の方法
HK40098371A (en) A pharmaceutical combination for the treatment of a cancer
RU2801665C2 (ru) Фармацевтическая комбинация для лечения рака
KR20160037233A (ko) 급성 골수성 백혈병 및 골수형성이상 증후군의 치료를 위한 데시타빈과 병용된 볼라세르티브
JP2020528418A (ja) ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
Neitzel Synergism of Lipoates and Established Anticancer Drugs in Cell and Mouse Models of Colorectal Cancer
KR20160035067A (ko) 급성 골수성 백혈병 및 골수형성이상 증후군의 치료를 위한 아자시티딘과 병용된 볼라세르티브
HK40120326A (zh) 用於治疗癌症的药物组合
IL295067A (en) Pharmaceutical combination for cancer treatment
JP2025525510A (ja) Ｂｃｌ－２阻害剤を含む癌併用療法
George et al. HORMONE THERAPY

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230512

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241008

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241230

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250513

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250513

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20250826

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250918

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251104

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251104